← Leaderboards
David Alan Drew
Tufts Medical Center
$1,756,066
Attributed
$2,553,816
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $427.7K · FY2016–25$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,553,816 · 2
By mechanism
R01$1,595,501 · 1
K23$958,315 · 1
Top collaborators
- Javier A. Neyra5 shared
Most similar at Tufts Medical Center
Same institution · by research overlap
- Joachim H Ix$16,690,262
- Orlando M Gutierrez$29,690,151
- Michael G Shlipak$18,418,069
- Mark J Sarnak$10,155,302
- Shanthini Kasturi$620,441
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantMineralsMortalityHypertensionKidney DiseasesMetabolismIntervention TrialFibroblast Growth Factor 23Clinical ResearchHigh RiskKidneyCohortBlood PressureKnockout MiceAffectCardiovascular Risk FactorEventExhibitsBiological MarkersChronic Kidney FailureHeartCardiovascular DiseasesBloodRenal Function
Grant awards (10)
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial$301,530
R01 · FY2025 · DK · contact PI
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial$289,468
R01 · FY2024 · DK · contact PI
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial$277,902
R01 · FY2023 · DK · contact PI
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial$298,859
R01 · FY2022 · DK · contact PI
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial$427,742
R01 · FY2021 · DK · contact PI
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney disease$194,400
K23 · FY2020 · DK · contact PI
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney disease$194,400
K23 · FY2019 · DK · contact PI
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney disease$194,400
K23 · FY2018 · DK · contact PI
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney disease$193,839
K23 · FY2017 · DK · contact PI
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney disease$181,276
K23 · FY2016 · DK · contact PI